deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02622321

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors

Sponsor: Chugai Pharmaceutical

Conditions Hemophilia A
Interventions Emicizumab aPCC rFVIIa
Updated 24 times since 2017 Last updated: May 26, 2021 Started: Nov 18, 2015 Primary completion: Oct 25, 2016 Completion: Dec 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hemophilia A and is currently completed. Chugai Pharmaceutical leads this study, which shows 24 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2021 — Sep 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 19 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Sep 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  16. Jul 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

  17. Jun 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  18. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chugai Pharmaceutical
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Atlanta, United States , Auckland, New Zealand , Aurora, United States , Bonn, Germany , Boston, United States , Bron, France , Camperdown, Australia , Cardiff, United Kingdom , Detroit, United States and 34 more locations